Vimarsana
Biggest News Aggregation in the World

Page 5 - Mark Lappe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Lappe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Lappe Today - Breaking & Trending Today

Forget crypto winter. In biotech, it's been freezing for months - Vimarsana News

Forget crypto winter. In biotech, it's been freezing for months

One exec compares the environment to a hurricane.

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 - Vimarsana News

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 - Vimarsana News

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency - Vimarsana News

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data - Vimarsana News

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...